StockNews.AI
BIO
StockNews.AI
204 days

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

1. Bio-Rad will report Q4 and full-year 2024 results on February 13, 2025. 2. A conference call will follow at 2 PM PT, accessible via several methods. 3. Bio-Rad generated $2.7 billion in revenue in 2023, signaling organizational stability. 4. Bio-Rad serves diverse clients, enhancing its market position in diagnostics. 5. The webcast will be available for a year, promoting transparency with investors.

Earnings
+2.27%Current Return
VS
+0.86%S&P 500
$358.8701/27 05:14 PM EDTEvent Start
$36701/28 11:42 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings could reflect strong financial performance, potentially boosting BIO's stock.

How important is it?

Earnings results are crucial indicators for investor confidence and stock price.

Why Short Term?

Earnings reports typically have immediate effects on stock prices.

Related Companies

BIOBIO.B
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Related News